173 related articles for article (PubMed ID: 30648509)
21. Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.
Hortobagyi GN; Zheng M; Mohanlal R
Oncologist; 2019 Feb; 24(2):178-184. PubMed ID: 30297386
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
24. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
[TBL] [Abstract][Full Text] [Related]
25. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
26. Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo.
Baranyi M; Rittler D; Molnár E; Shirasawa S; Jalsovszky I; Varga IK; Hegedűs L; Németh A; Dank M; Aigner C; Tóvári J; Tímár J; Hegedűs B; Garay T
Pathol Oncol Res; 2020 Jul; 26(3):1957-1969. PubMed ID: 31902117
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.
Rouhrazi H; Turgan N; Oktem G
Biotech Histochem; 2018; 93(2):77-88. PubMed ID: 29300112
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
Asbagh LA; Uzunoglu S; Cal C
Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro.
Fu D; He X; Yang S; Xu W; Lin T; Feng X
BMC Musculoskelet Disord; 2011 Jun; 12():146. PubMed ID: 21718535
[TBL] [Abstract][Full Text] [Related]
33. RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo.
Alkasalias T; Alexeyenko A; Hennig K; Danielsson F; Lebbink RJ; Fielden M; Turunen SP; Lehti K; Kashuba V; Madapura HS; Bozoky B; Lundberg E; Balland M; Guvén H; Klein G; Gad AK; Pavlova T
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1413-E1421. PubMed ID: 28174275
[TBL] [Abstract][Full Text] [Related]
34. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates.
Yamazaki D; Kurisu S; Takenawa T
Oncogene; 2009 Apr; 28(13):1570-83. PubMed ID: 19234490
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
36. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
Taddei ML; Parri M; Angelucci A; Bianchini F; Marconi C; Giannoni E; Raugei G; Bologna M; Calorini L; Chiarugi P
Mol Cancer Res; 2011 Feb; 9(2):149-60. PubMed ID: 21205836
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of zoledronic acid on human vascular smooth muscle cells.
Albadawi H; Haurani MJ; Oklu R; Trubiano JP; Laub PJ; Yoo HJ; Watkins MT
J Surg Res; 2013 Jun; 182(2):339-46. PubMed ID: 23164362
[TBL] [Abstract][Full Text] [Related]
39. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion.
Hodge JC; Bub J; Kaul S; Kajdacsy-Balla A; Lindholm PF
Cancer Res; 2003 Mar; 63(6):1359-64. PubMed ID: 12649199
[TBL] [Abstract][Full Text] [Related]
40. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
